ELAB
PMGC Holdings Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.21
−0.38%Year over year
Reported trailing growth
- Revenue
- +303.5%
- EBITDA
- —
- EBIT
- —
- EPS
- +87.1%
- Free cash flow
- +3.0%
- Operating cash flow
- +4.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -8.3%
- EBITDA
- —
- EBIT
- —
- Net income
- -23.4%
- EPS
- +94.3%
- Free cash flow
- -16.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026